Leadership & Staff


The BRI is led by three faculty directors and the Chief Academic Officer. As members of the BRI Executive Committee (EC), these representatives are responsible for directing the BRI and for representing the BWH research community inside and outside the institution.

Ursula Kaiser

Ursula Kaiser, MD

Charles N Serhan photo

Charles N. Serhan, PhD, DSc

Paul Andorson

Chief Academic Officer
Paul Anderson, MD, PhD


Immediate Past-Director
Marc Sabatine, MD, MPH


Executive Director
Jacqueline Slavik, PhD, MMSc

Call for Nominations for BRI Director

The Brigham Research Institute (BRI) is led by three faculty Directors; a current Director, a co-Director, and a past-Director. The Director serves two years in each position for a total of six years on the BRI Executive Committee, with position changes that align with the fiscal year. The BRI welcomes nominations for the next BRI Director; the incumbent will assume the role of BRI co-director on October 1, 2022. The deadline to submit nominations is Monday, April 25th. Self-nominations are acceptable. To apply or nominate a colleague for consideration visit link below.

2022 ROC Guest Slots Available

The BRI Executive Committee is opening three guest slots at each monthly ROC meeting. If you wish to attend a ROC meeting, please sign up here (note that you may only attend one ROC meeting per calendar year as a guest). Feel free to email bwhbri@partners.org with questions.

BWH Research Oversight Committee (ROC) Membership Application

We invite BWH entities not currently represented on the ROC through another category/office to apply for membership.Please note that all ROC members are required to attend monthly meetings, review and/or vote on topics discussed and disseminate relevant information shared at these forums to their respective communities. If you would like to preview a meeting before applying for membership, please see above to sign up for a guest spot at a future ROC meeting.

The BRI Research Oversight Committee

The BRI is governed by the ROC which is made up of the BRI Executive Committee, department chairs or their representatives, BRI Center and Program Co-Chairs, elected members and various BWH/Partners leaders and ad hoc members. The ROC was established to foster transparency and accountability in the decision-making process for the research enterprise and to plan new strategic initiatives; the composition of the ROC is intended to collectively reflect the diversity of the BWH research community.
Research entities that are distinct from Hospital departments may request representation on the ROC by sending a brief statement of interest to BWHBRI@partners.org.


James P. Rathmell, MD (Chair)
Jochen D. Muehlschlegel,  MD (Alternate)


Thomas S. Kupper, MD (Chair)
Hans Widlund, PhD (Representative)


Emergency Medicine
Michael J. VanRooyen, MD, MPH (Chair)


Joseph Loscalzo, MD, PhD (Chair)
Nancy Berliner, MD (Representative)


Tracy T. Batchelor, MD, MPH (Chair)
Francisco Quintana, PhD (Representative)


Ennio A. Chiocca, MD, PhD (Chair)
Nathalie Agar, PhD (Representative)


Newborn Medicine
Terrie E. Inder, MBCHB (Chair)
Kate Gregory, PhD, RN (Alternate)


Patricia Dykes, RN, DNSc, MA

Nawal M. Nour, MD,  MPH (Chair)
Cynthia Morton, PhD (Representative)


Orthopedic Surgery
James D. Kang, MD (Chair)
Julie Glowacki, PhD (Alternate)



Jon Christopher Aster, MD, PhD (Interim Chair)
Sean R. Stowell, MD, PhD (Alternate)


Physical Medicine and Rehabilitation
Ross D. Zafonte, DO (Chair)


David  A. Silbersweig, MD (Chair)
Katherine Burdick, PhD (Representative)


Radiation Oncology
Daphne A. Haas-Kogan, MD (Chair)
G. Mike Makrigiorgos, PhD, DABMP/DABR (Alternate)
Ross I. Berbeco, PhD (Second Alternate)


James A. Brink, MD (Chair)
Noby Hata, PhD (Representative)


Gerard M. Doherty, MD (Chair)
Steve Mentzer, MD (Representative)
James Lederer,  PhD (Alternate)


Cancer Research Center
Jon Christopher Aster, MD, PhD


Cardiovascular, Diabetes & Metabolic Disorders Research Center
Mark Feinberg, MD
Marie McDonnell, MD
C. Keith Ozaki, MD


Connors-BRI Center for Research on Women’s Health & Gender Biology
Laura Holsen, PhD
Hadine Joffe, MD, MSc
Kathryn Rexrode, MD


Genomics Center
Robert Green, MD, MPH
Calum MacRae, MD, PhD
Christine Seidman, MD

Infectious and Immunologic Diseases Research Center
Ana Anderson, PhD
Rachael Clark, MD, PhD
Matthew K. Waldor, MD, PhD


Lung Research Center
Raphael Bueno, MD
Bruce Levy, MD
Edwin Silverman, MD, PhD


Musculoskeletal Research Center
Jeff Duryea, PhD
Nancy Ann Shadick, MD, MPH

Neurosciences Research Center
Alexandra Golby, MD
Emily Stern, MD


Patient Centered Comparative Effectiveness Research Center
Elliot Israel, MD
Joel Weissman, PhD


Regenerative Medicine Research Center



Scott Weiss, MD

Biomedical Imaging

Clare Tempany, MD

Clinical Investigation

Lindsey R. Baden, MD

Pre-Clinical Models

Daniela Dinulescu, PhD

Cynthia Lemere, PhD

Arlene Sharpe, MD, PhD


Junior Faculty
Martin Hemberg, PhD
Basic Research

Amanda Lyall, PhD
Clinical Research

Naoko Sasamoto, MD, MPH
Population Science 

Primavera Spagnola, MD, PhD
Clinical Research (Alternate)

Jen Stuart, ScD
Population Science (Alternate)

Senior Faculty
Yohannes Tesfaigzi, PhD
Basic Research

Gad Marshall, MD
Clinical Research

Alexander Turchin, MD
Population Science

Matthew Spite, PhD
Basic Research (Alternate)

Postdoctoral Fellows

Sourabh Soni, PhD

First alternate: Bidisha (Eshaani) Mitra, PhD

Second alternate: Robert Nshimiyimana, PhD

Research Administrators

Laurel Cobban, MS
Bonnie Wheeler, MBA, CRA

Additional Members

President, Brigham and Women’s Hospital
Robert S.D. Higgins, MD, MSHA


Chief Medical Officer, Brigham and Women’s Hospital
Sunil Eappen, MD, MBA


President of the Brigham and Women’s Physicians Organization
Giles W.L. Boland, MD


Harvard Catalyst Representative
Elliot Antman, MD



  • Susan Rapple, Chief Development Officer
  • Kristin Garrity, Associate Vice President, Development, Brigham and Women’s Hospital
  • Linda Jones, Associate Vice President for Institutional Giving


Senior Science Communication Specialist
Haley Bridger


Chief Academic Officer, Mass General Brigham
Ravi I. Thadhani, MD, MPH


Vice President, Clinical Trials Research and Administration, Mass General Brigham
Stephen D. Wiviott, MD, FACC



Thomas Michel, PhD


CIMIT Site Miner, BWH

Frederick Schoen, MD, PhD


Partners Innovation

  • Christopher Coburn, Chief Innovation Officer, Mass General Brigham
  • Glenn Miller, PhD


Digital Innovation Hub and Chief Information Officer
Adam Landman, MD, MS, MIS, MHS


Partners Research Management
Andrew Chase


Research Administration and Compliance
Allison Moriarty, MPH


Brigham Education Institute
Erik K. Alexander, MD, FACP

Scientific Advisory Board
  • Sangeeta Bhatia, MD, PhD, Professor, Massachusetts Institute of Technology (MIT)
  • James Bradner, MD President Novartis Institutes for BioMedical Research (NIBR), Novartis
  • Gerald Chan, PhD Founder, Morningside Group Ltd.
  • Susan Hockfield, PhD President Emerita and Professor of Neuroscience, Massachusetts Institute of Technology (MIT)
  • Terry McGuire, MBA, MS Co-Founder and General Partner Polaris
  • Aviv Regev, PhD, Executive Vice President of Research, Roche
  • Geoff Smith, JD  Professor of Biology; Core Member, Broad Institute; Investigator, Howard Hughes Medical Institute
  • Michael Rosenblatt, MD Chief Medical Officer, Flagship Ventures
  • Geoff Smith, JD Managing Partner, Digitalis Ventures
  • Elias Zerhouni, MD President, Global Research & Development, Sanofi

The BRI Administrative Staff


Dr. Jacqueline M. Slavik is the executive director of the Brigham Research Institute (BRI) at Brigham and Women’s Hospital. In this role she shapes and implements the BRI’s overarching mission to accelerate discoveries that improve human health by fostering groundbreaking, interdepartmental, and interdisciplinary research, ranging from basic fundamental studies to clinical innovations.  She manages a team who works to provide a clear voice for the entire BWH research community, raise the profile of research at BWH, develop mission-centric collaborations with external entities and engage the scientific community in fundraising. Dr. Slavik received her PhD in Immunology from Harvard University, a Master of Medical Science from Harvard University and a BS in Biology from State University of New York at Albany. Dr. Slavik did her postdoctoral fellowship in the Center for Neurologic Diseases in the Department of Neurology at BWH, and held a faculty appointment as instructor in Neurology at Harvard Medical School prior to transitioning to the role of senior program manager at the BRI, from which she moved into her current leadership role. Her research interests include T lymphocytes and T lymphocyte signaling and their involvement in cancer and autoimmune diseases such as multiple sclerosis.


Dr. Anu Swaminathan serves as the Director for Scientific Programs and Partnerships at the Brigham Research Institute (BRI). In this role, she drives a broad range of activities related to the BRI’s multiple research centers, programs and other pan-institute initiatives with the ultimate goals of increasing the visibility of the exciting research happening at BWH and catalyzing fundraising for the same in order to fuel the discovery and innovation engine of the hospital. As part of this mandate, she leads efforts to establish new research collaborations within BWH as well as with external entities including industry; diversify the funding portfolio of researchers and clinician scientists and; foster institutional involvement and community building within the hospital’s research fraternity. Anu has a PhD in Biochemistry from the University of Connecticut and brings an eclectic blend of professional experiences spanning basic research, technology commercialization, policy making and administration to her current role.


Dr. James (Trey) Toombs is the Program Manager for the Brigham Research Institute (BRI) where he manages the activities of the research centers and programs sponsored by the BRI. In this role, Dr. Toombs works closely with center and program leaders to develop and execute initiatives to raise the visibility of the research being conducted at BWH and foster new interdisciplinary and interdepartmental research programs. Prior to joining the BRI, Dr. Toombs was a research fellow at Massachusetts General Hospital where he employed NextGen sequencing technologies to probe the role of a germline-specific class of small non-coding RNAs (piRNAs) in regulating the maternal transcriptome in Xenopus oocytes. Prior to that, he received his PhD in Biochemistry and Molecular Biology from Colorado State University where he performed a mutational analysis to identify the molecular determinants of prion formation in yeast and developed a robust algorithm capable of both predicting the prion forming propensities of known proteins and rationally designing new prion forming proteins de novo. Dr. Toombs brings the analytical and problem solving skills he developed during his years as a research trainee to his current role of managing the research centers and programs at the BRI.


Alexandra Gallant is the Web Media Manager & Creative Designer at the Brigham Research Institute. Her role is focused on identifying ways to use visual communication tools to support the efforts of the research community.  With an emphasis on user experience and design standards,  she provides creative direction for all BRI initiatives, including the development of research web sites, email communication  vehicles and print collateral.  She studied Criminal Justice and English at Northeastern University. She is also an accomplished artist and illustrator.


Amanda Komarowski is a Web Designer at the Brigham Research Institute. She manages the operations for the development of new research websites for laboratories and research groups, and assists with a range of online communication efforts directed at both internal and external audiences. Amanda graduated from Bridgewater State University in 2010, with a degree in Graphic Design & Communication Studies.


Sara Yohannes is the Event Manager at the Brigham Research Institute (BRI). She is responsible for managing and executing all events for the BRI. She plans around 100 events a year ranging from 20 – 1,000 attendees. Also, works in partnership with other departments and institutions to collaborate on new events to achieve the goals of the BRI and the Brigham. Sara volunteered at the MGB Center for COVID Innovation (MGB CCI) as administrative support during the height of the COVID pandemic, and was cited on the evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2 publication. She previously worked at the Brigham and Women’s Hospital Orthopedic and Arthritis Center and the AIDS Action Committee of Massachusetts. Sara graduated from Suffolk University with a Bachelor of Science in Business Administration in 2012.


Rowan received their B.A. in Gender and Sexuality Studies from Brown University. They are passionate about equity in research and healthcare administration and excited to support the research community at BWH.


Dr. David serves as Innovation Strategist at the BRI, in addition to being Founder and Managing Director of Pharmagellan, a Boston-area biotech consulting firm. After studying molecular biophysics and biochemistry at Yale, Dr. David received his M.D. and Ph.D. degrees from Columbia University’s College of Physicians and Surgeons. Dr. David completed his clinical training in anatomic pathology at Brigham and Women’s Hospital, and then served as Instructor in Pathology at Harvard Medical School and Brigham and Women’s, where he researched cell signaling in cancer and kidney development. As Director in the consulting arm of Leerink Partners, a leading healthcare investment bank, Dr. David led advisory engagements for corporate, commercial, R&D, business development, and investor clients across all major therapeutic areas and business sectors, including biopharma, devices, diagnostics, life sciences tools, and healthcare services. He also co-founded Leerink’s Transactional Consulting practice, which advised financial and strategic investors and early-stage companies side-by-side with Leerink’s investment banking team. Dr. David also served as Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit, where he led business strategy efforts from target identification through Phase 2a, spearheaded initiatives in end-to-end franchise strategy and portfolio valuation, led external communications focused on R&D collaborators and investors, and provided commercial support to pipeline projects and in-licensing teams.   Dr. David writes about biomedical innovation at Forbes.com and the Pharmagellan blog, and maintains an active presence on Twitter (@Frank_S_David).


Josephine ,,,,